SCM
BRLI

Siphron Capital Management’s BIO-REFERENCE LABS INC-NEW- BRLI Stock Holding History

Siphron Capital Management’s Portfolio BRLI Stock Details BRLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-73
Closed -$2K – 83
2013
Q3 		$2K Hold
73
– – ﹤0.01% 77
2013
Q2 		$2K Buy
+73
New +$2.01K ﹤0.01% 76

Other funds holding BRLI

RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Tiger Global Management
Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CM
CS McKee Pittsburgh, Pennsylvania $1.09B AUM 31.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Siphron Capital Management's BRLI Position: Q4 2013 in Review

Siphron Capital Management sold out of BIO-REFERENCE LABS INC-NEW- (BRLI) in Q4 2013, closing a stake of 73 shares — an estimated $2K sold.

Siphron Capital Management first reported a position in BRLI in Q2 2013 and held it in 2 quarters. The position peaked at $2K in Q3 2013. 175 funds tracked by Wall St. Rank hold BRLI as of Q4 2013.

  • Siphron Capital Management reported no remaining BIO-REFERENCE LABS INC-NEW- position as of Q4 2013 after selling out during the quarter.
  • Siphron Capital Management sold 73 BIO-REFERENCE LABS INC-NEW- shares in Q4 2013, an estimated $2K.
  • Siphron Capital Management first reported a position in BIO-REFERENCE LABS INC-NEW- in Q2 2013 and held it in 2 quarters.
  • Siphron Capital Management's BIO-REFERENCE LABS INC-NEW- position peaked at $2K in Q3 2013.
  • 175 funds tracked by Wall St. Rank held BIO-REFERENCE LABS INC-NEW- as of Q4 2013.

Based on Siphron Capital Management's 13F filing for Q4 2013, filed 13 Feb 2014.